We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.23 | 0.77% | 30.25 | 30.15 | 30.26 | 30.28 | 30.07 | 30.10 | 2,908,982 | 22:20:00 |
By Colin Kellaher
Roche Holding AG's Spark Therapeutics unit on Tuesday said it signed a collaboration and option agreement with Senti Biosciences that could be worth more than $645 million to the privately held gene-circuit company.
Spark said the collaboration will combine its investigational gene therapies targeting the central nervous system, eye and liver with Senti's gene-circuit technology.
Spark said Senti will be responsible for designing, building and testing synthetic promoters for use in developing certain gene therapies, while Spark will have the option to license promoters and will be responsible for conducting preclinical, clinical and commercialization activities for any gene therapy candidates using the promoters.
Spark, which Roche acquired in 2019 for $4.8 billion, said the aggregate potential value of upfront, opt-in and milestone payments to South San Francisco, Calif.-based Senti could top $645 million.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 13, 2021 09:55 ET (13:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions